The Role of Artificial Intelligence in the Assessment of Multiparametric Resonance of the Prostate in Prostate Cancer Patients
Sponsor: IRCCS San Raffaele
Trial Details
| Condition | Prostate Cancer |
| Intervention | Quantib prostate (Quantib B.V. Rotterdam, The Netherlands) software |
| Status | Completed |
| Participants | 200 |
| Est. Completion | 2 Sept 2024 |
| Last Updated | 18 May 2026 |
Primary Outcome
To evaluate the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy in detecting csPCa of Quantib Prostate vs. traditional radiologist reading of mpMRI
Eligibility Criteria
Inclusion Criteria
Inclusion Criteria: 1. Men at least 18 years of age referred with clinical suspicion of prostate cancer 2. Men who have undergone mpMRI and subsequent targeted plus random systematic prostate biopsies 3. Available pathological report with details regarding the site of positive cores and grade group 4. Serum PSA ≤ 20 5. Patient who underwent a 1.5T mpMRI with or without endorectal coil with the following protocol restrictions and according to recent European Guidelines, each case containing at least the following sequences, will be considered: T2w * No fat suppression * At least axial acquisition * Max voxel size 1.0x1.0x3.0mm DWI * At least on b-value ≥800 s/mm\^2 required, ≥1400 s/mm\^2 preferred * ADC map required * Max voxel size: 2.0x2.0x4.0mm * Axial scanning protocol only DCE scan * Recommended temporal resolution \<15s * Axial scanning protocol only Exclusion Criteria: NA
Trial Sites
Countries
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service